18F-FDG PET/CT 早期预测放射性碘难治性不可切除或晚期甲状腺癌患者仑伐替尼治疗结局:一项前瞻性、多中心、非随机研究
这项前瞻性、非随机、多中心研究纳入21例病理确诊的放射性碘难治性分化型甲状腺癌患者,在仑伐替尼初始剂量24 mg治疗1周后行18F-FDG PET/CT,以至少4周后的增强CT为金标准。SUVmax预测治疗反应的ROC-AUC为0.714,最佳截断值15.211,敏感度0.583、特异度0.857;作者认为治疗1周后PET/CT可能预测治疗结局。
要点
- 仑伐替尼初始剂量24 mg治疗1周后行18F-FDG PET/CT,SUVmax预测治疗反应的ROC-AUC为0.714。
- SUVmax最佳截断值15.211,敏感度0.583、特异度0.857。
- 中位无进展生存期:低于截断值组26.3个月 vs 高于截断值组19.7个月(P=0.078)。
核心结论
- 由于PET/CT上FDG摄取下降,仑伐替尼的治疗效应较CT更早被检出。
- 仑伐替尼治疗开始1周后行PET/CT检查可能预测分化型甲状腺癌患者的治疗结局。
研究设计与样本
- 前瞻性、非随机、多中心研究,纳入21例病理确诊且病灶对放射性碘治疗难治的分化型甲状腺癌患者。
- 患者接受仑伐替尼初始剂量24 mg治疗,治疗开始1周后行PET/CT检查。
- 以至少4周后进行的增强CT作为评估金标准。
- 主要终点为比较PET/CT获得的SUVmax与增强CT的判别能力,采用ROC-AUC曲线评估。
主要发现
- 仑伐替尼治疗1周后SUVmax的ROC曲线分析AUC为0.714。
- SUVmax预测治疗反应的最佳截断值为15.211,该截断值的敏感度为0.583、特异度为0.857。
- 中位无进展生存期:低于截断值组26.3个月 vs 高于截断值组19.7个月(P=0.078)。
关键数值与推荐
- 仑伐替尼初始剂量为24 mg。
- PET/CT检查时间为仑伐替尼治疗开始后1周。
- 增强CT安排在至少4周后作为评估金标准。
- SUVmax预测治疗反应的ROC-AUC为0.714,最佳截断值15.211,敏感度0.583、特异度0.857。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes. RESULTS: This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion. Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation. Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation. The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT. Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve. Twenty-one patients were included in this analysis. Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment. The best cut-off value for the treatment response for SUVmax was 15.211. The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively. The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value (P = 0.078). CONCLUSIONS: The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT. PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC. TRIAL REGISTRATION: This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016.
引用
- Takeuchi S, Hirata K, Magota K, et al. Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study. EJNMMI Res. 2023. PMID: 37460834. doi:10.1186/s13550-023-01019-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。